Regeneron third-quarter profit easily tops Street view on Eylea, Dupixent sales

(Reuters) - Regeneron Pharmaceuticals Inc on Wednesday reported third-quarter profit that sailed past Wall Street estimates on the strength of increased demand for flagship eye treatment Eylea and its new eczema drug Dupixent, boosting its shares almost 7 percent.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news